Digital Breast Tomosynthesis Mammography Unit

Introduced ‘HESTIA’ with a DBT function.input:
output:Obtained official certification for manufacturing and sales from the Ministry of Food and Drug Safety.input:
output:Successfully localized equipment and reduced dependence on foreign equipment.input:
output: Genoray (CEO, Byung-Uk Park), a global imaging diagnostic medical device company, announced on the 10th that it has successfully obtained DBT breast cancer diagnosis system manufacturing and sales certification from the Ministry of Food and Drug Safety (MFDS) in Korea for the first time. Genoray intends to exhibit the DBT breast cancer diagnosis system ‘HESTIA’ at the ’36th International Medical Equipment & Hospital Equipment Show (KIMES2021)’. Digital Breast Tomosynthesis (DBT) is a technology that allows for the observation of a tomography image of the breast, thereby facilitating a more precise diagnosis of breast cancer. This technology is in contrast to conventional 2D equipment. In addition, the diagnosis of microcalcifications and tumors in numerous dense breasts in Asian women, including Korea, can be optimized by increasing the breast cancer diagnosis efficiency by over 30%.>

There is no domestic equipment that can compete with foreign equipment of the same type in the domestic market, which is why it has exclusively relied on costly foreign equipment. The release of ‘HESTIA’ this time allows Genoray to enter the treatment market, as well as hospitals, clinics, and examination centers, which were considering the introduction due to the high cost of equipment and maintenance.